- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lucid Diagnostics Inc (LUCD)
Lucid Diagnostics Inc stock price live, this page displays NASDAQ LUCD stock exchange data. View the LUCD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lucid Diagnostics Inc real time stock price chart below.
What Is the Lucid Diagnostics Inc Stock Price Today?
The Lucid Diagnostics Inc stock price today is 1.0000.
What Is the Stock Symbol for Lucid Diagnostics Inc?
The stock symbol for Lucid Diagnostics Inc is ""LUCD.""
What Stock Exchange Does Lucid Diagnostics Inc Trade On?
Lucid Diagnostics Inc is listed and trades on the NASDAQ stock exchange.
Is Lucid Diagnostics Inc a Good Stock to Buy?
Determining whether Lucid Diagnostics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LUCD quote. (ISIN: US54948X1090)
What Is the Lucid Diagnostics Inc Stock Price Today?
The Lucid Diagnostics Inc stock price today is 1.0000.
What Is the Stock Symbol for Lucid Diagnostics Inc?
The stock symbol for Lucid Diagnostics Inc is ""LUCD.""
What Stock Exchange Does Lucid Diagnostics Inc Trade On?
Lucid Diagnostics Inc is listed and trades on the NASDAQ stock exchange.
Is Lucid Diagnostics Inc a Good Stock to Buy?
Determining whether Lucid Diagnostics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LUCD quote. (ISIN: US54948X1090)
1.0000
-0.0200(-1.96%)
Closed·
After Hours
1.0099+0.0099(+0.99%)
·
Fair Value
An estimate of a Lucid Diagnostics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9663
1.0496
52 wk Range
0.7300
1.8000
LUCD Scorecard
Full Analysis
Quickly burning through cash
Earnings results expected in 13 days
More Info
Fair Value
An estimate of a Lucid Diagnostics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.96631.0496
52 wk Range
0.73001.8000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LUCD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Lucid Diagnostics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
3.7917
Upside
+279.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Lucid Diagnostics Inc Company Profile
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc SWOT Analysis
Market Disruption | Lucid Diagnostics aims to revolutionize BE-EAC screening with EsoGuard/EsoCheck technology, targeting a $25 billion U.S. market opportunity |
Financial Crossroads | Despite 179% YoY revenue growth, LUCD faces challenges with cash burn and revised 2025 revenue projections, reflecting market uncertainties |
Reimbursement Hurdles | Progress in clinical validation studies bolsters reimbursement efforts, but pricing pressures could impact future revenue and market adoption |
Strategic Outlook | Analysts set price targets between $2.00 and $3.00, as LUCD navigates growth challenges and explores potential market expansion opportunities |
Lucid Diagnostics Inc Earnings Call Summary for Q1/2025
- Lucid Diagnostics reported Q1 2025 revenue of $800,000, with 3,034 EsoGuard tests performed, exceeding expectations.
- Cash reserves increased to $41 million post-April offering; company secured first positive policy coverage from Highmark Blue Cross Blue Shield.
- Targeting $60 billion market; forecasts revenue growth to $24.05 million by FY2026, pending Medicare coverage decision and NIH study results.
- Quarterly burn rate of $11.3 million; company navigating reimbursement challenges with major insurers while expanding testing channels.
- CEO emphasizes favorable commercial setup; CFO targets 40% of 30 million patient market, demonstrating confidence in growth strategy.
Last Updated: 14/05/2025, 14:54
Read Full TranscriptCompare LUCD to Peers and Sector
Metrics to compare | LUCD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLUCDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −3.8x | −0.5x | |
PEG Ratio | −1.06 | −0.28 | 0.00 | |
Price/Book | −1.8x | 2.5x | 2.6x | |
Price / LTM Sales | 25.9x | 3.7x | 3.3x | |
Upside (Analyst Target) | 194.1% | 15.2% | 43.5% | |
Fair Value Upside | Unlock | 5.3% | 6.3% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 3.7917
(+279.17% Upside)
Earnings
Latest Release
May 14, 2025
EPS / Forecast
-0.16 / -0.19
Revenue / Forecast
830.00K / 1.87M
People Also Watch
FAQ
What Stock Exchange Does Lucid Diagnostics Trade On?
Lucid Diagnostics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Lucid Diagnostics?
The stock symbol for Lucid Diagnostics is "LUCD."
What Is the Lucid Diagnostics Market Cap?
As of today, Lucid Diagnostics market cap is 110.36M.
What Is Lucid Diagnostics's Earnings Per Share (TTM)?
The Lucid Diagnostics EPS (TTM) is -1.26.
When Is the Next Lucid Diagnostics Earnings Date?
Lucid Diagnostics will release its next earnings report on 17 Aug 2025.
From a Technical Analysis Perspective, Is LUCD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Lucid Diagnostics Stock Split?
Lucid Diagnostics has split 0 times.
How Many Employees Does Lucid Diagnostics Have?
Lucid Diagnostics has 72 employees.
What is the current trading status of Lucid Diagnostics (LUCD)?
As of 05 Aug 2025, Lucid Diagnostics (LUCD) is trading at a price of 1.00, with a previous close of 1.02. The stock has fluctuated within a day range of 0.97 to 1.05, while its 52-week range spans from 0.73 to 1.80.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.